Leo Pharma files for marketing approval of tralokinumab in Japan

Pharmaceutical company Leo Pharma has announced it has filed a marketing authorization application with the Japanese health authority for the moderate-to-severe atopic eczema drug, tralokinumab.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

Leo Pharma has filed an application for marketing authorization of tralokinumab, the company’s treatment for patients with moderate-to-severe atopic eczema, in Japan, the company announces in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading